Literature DB >> 21680553

Surgery for hemoptysis in various pulmonary tuberculous lesions: a prospective study.

Alaa Brik1, Abdel-Maged Salem, Amira Shoukry, Waheed Shouman.   

Abstract

Hemoptysis due to pulmonary tuberculous lesions is a common cause of morbidity, and occasionally mortality. The aim of this study is to evaluate the surgical outcome of hemoptysis in patients with various tuberculous pulmonary lesions. A total of 45 cases who underwent surgical procedures for various pulmonary tuberculous lesions with hemoptysis were included in this study. Sixteen patients underwent surgical management within one week of the attack of hemoptysis (group A), the other 29 patients underwent surgery one week after the attack (group B). Hemoptysis was classified into minor, major and massive hemoptysis. Major and massive hemoptysis were the common presentation of group A and tuberculous cavities were the most common lung lesions in both groups (37.7%). Lobectomy was the main surgical procedure performed in both groups (51.1%). Bronchopleural fistula occurred in one case in each group after right pneumonectomy. There was one case (6.2%) of mortality in group A. Tuberculous cavity is the common pulmonary lesion which can result in major and massive hemoptysis, therefore, we recommend early surgical resection of tuberculous cavities to avoid life-threatening hemoptysis. Limited resection should be avoided to prevent recurrence.

Entities:  

Mesh:

Year:  2011        PMID: 21680553     DOI: 10.1510/icvts.2011.270991

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  2 in total

Review 1.  The Diagnosis and Treatment of Hemoptysis.

Authors:  Harald Ittrich; Maximilian Bockhorn; Hans Klose; Marcel Simon
Journal:  Dtsch Arztebl Int       Date:  2017-06-05       Impact factor: 5.594

2.  Surgery for hemoptysis in patients with benign lung disease.

Authors:  Ju Sik Yun; Sang Yun Song; Kook Joo Na; Seok Kim; Keun-Ho Jang; In Seok Jeong; Sang Gi Oh
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.